🇨🇦 Canada Country × Condition
lung cancer Clinical Trials in Canada
Active clinical trials for lung cancer with research sites in Canada. All data sourced live from ClinicalTrials.gov — updated daily.
Active Trials: 5 // Recruiting: 5 Phases: Phase 2, Phase 1, Phase 2 // Updated: Daily
Total Trials
5
Recruiting Now
5
Country
🇨🇦 Canada
Active Trials in Canada (5)
NCT05849129 Phase 2
Recruiting
Adjunctive Intravenous Ascorbic Acid for Advanced Non-Small Cell Lung Cancer
Enrollment
90 pts
Country
🇨🇦 Canada
The Canadian College of Naturopathi...
View Trial → NCT06424327
Recruiting
A Registry for People With Lung Cancer
Enrollment
600 pts
Country
🇨🇦 Canada
Memorial Sloan Kettering Cancer Cen...
View Trial → NCT06973161
Recruiting
ESPERANZA: External Control Arm Study for T-DXd for Patients With HER2 IHC3+ Solid Tumors
Enrollment
105 pts
Country
🇨🇦 Canada
AstraZeneca
View Trial → NCT05509751
Recruiting
The SOAR Study: a Study of Geriatric Assessment and Exercise for Older Adults and Their Support Person
Enrollment
60 pts
Country
🇨🇦 Canada
Martine Puts
View Trial → NCT04459065 Phase 1, Phase 2
Recruiting
Evaluation of IRDye800CW-nimotuzumab in Lung Cancer Surgery
Enrollment
36 pts
Country
🇨🇦 Canada
University of Saskatchewan
View Trial → Frequently Asked Questions
How many lung cancer clinical trials are active in Canada?
There are currently 5 active clinical trials for lung cancer with sites in Canada, of which 5 are actively recruiting patients.
How can I join a lung cancer clinical trial in Canada?
To join a lung cancer clinical trial in Canada, select a recruiting trial below and check the eligibility criteria. Contact the trial's principal investigator or the listed site in Canada directly. All trials listed here are sourced from ClinicalTrials.gov, the official U.S. registry of clinical studies.
What phases are lung cancer trials in Canada?
Active lung cancer trials in Canada span Phase 2, Phase 1, Phase 2. Phase I trials test safety, Phase II test efficacy, and Phase III compare against standard treatments in larger patient populations.